IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11203611 B1

PDFFull Text
Date of Patent:
Dec. 21, 2021

Filed:

Apr. 13, 2018

Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use

Applicant:

Solstice Biologics, Ltd., Dublin, IE;

Inventors:

Sukumar Sakamuri, San Diego, CA (US);

Curt W. Bradshaw, San Diego, CA (US);

Son Lam, San Diego, CA (US);

Joseph Stock, San Diego, CA (US);

Edward Hyungsuk Ha, Solana Beach, CA (US);

Laxman Eltepu, San Diego, CA (US);

Dingguo Liu, San Diego, CA (US);

Bin Liu, San Diego, CA (US);

Giuseppe Dello Iacono, Oceanside, CA (US);

Bryan R. Meade, San Diego, CA (US);

Ayman Kabakibi, San Diego, CA (US);

Assignee:

TOLLNINE, INC., San Francisco, CA (US);

Attorney:

Jones Day

Primary Examiner:

Sean McGarry

Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/117 (2010.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 47/60 (2017.01); A61K 31/7125 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01);
U.S. Cl.
CPC ...
C07H 21/04 (2013.01); A61K 31/7125 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 47/60 (2017.08); A61K 47/6807 (2017.08); A61K 47/6849 (2017.08); A61K 47/6883 (2017.08); A61P 35/00 (2018.01); C07K 7/06 (2013.01); C07K 16/2803 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2833 (2013.01); C07K 16/2851 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/3084 (2013.01); C12N 15/117 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/572 (2013.01); C07K 2319/40 (2013.01); C12N 2310/17 (2013.01); C12N 2310/311 (2013.01); C12N 2310/315 (2013.01); C12N 2310/332 (2013.01); C12N 2310/3513 (2013.01); C12N 2310/3515 (2013.01); C12N 2310/51 (2013.01);
Abstract

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

Find Patent Forward Citations

Loading…